Create Medicines closed a $122 million Series B financing to support its pipeline of in vivo CAR therapies delivered by liquid nanoparticles. The company said the funding runway is expected to last through 2028 as it advances multiple programs. Create Medicines’ approach is aimed at expressing CARs directly in patients’ T cells, NK cells, and myeloid cells, avoiding ex vivo manufacturing. The capital will support four clinical programs targeting TROP2, GPC3, HER2, and a combined HER2 x TROP2 strategy. The company also described plans to extend its platform into autoimmune disease through B-cell depletion and to enter the clinic in 2026.